Biostage to delist from Nasdaq
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Biostage Inc. said Nasdaq will complete the delisting process for its common stock, after it failed to regain compliance with the rules.
The biotech company receive the notice of suspension in October. Concurrently, it started trading on the OTCQB marketplace under the symbol BSTG.
Biostage said the Nasdaq delisting will not affect its OTCQB marketplace listing.
